Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2012

View Archived Issues

Takeda Pharmaceutical offers overview of third quarter fiscal 2011

BiondVax's phase II flu vaccine trial meets primary safety endpoint

Debiopharm commences phase Ib expansion study of Debio-0932

Hanmi and AngioLab enter licensing agreement

Studies point to benefit of sonothrombolysis after stroke

New antiviral agents disclosed by Alla Chem

Alla Chem presents new androgen receptor antagonists

Latvian company patents novel agents for influenza

New protein kinase inhibitors synthesized by Chinese team

Trials indicate ipilimumab can be administered with cancer vaccines

Novel tissue engineering scaffolds tested in vivo

Hyundai Pharmaceutical discloses new GPR119 receptor agonists

Novartis to revise product information for Rasilez in the E.U.

GlaxoSmithKline provides regulatory update on Tykerb/Tyverb

NeuroPhage Pharmaceuticals receives funding from Michael J. Fox Foundation

GlaxoSmithKline receives CHMP opinion on Nimenrix

Collaborating Japanese universities identify new potential target for cancer therapy

Gilead Sciences reports on ELECTRON trial

New approval for Zelboraf

Dainippon Sumitomo seeks line extension for Amlodin in Japan

EMA committee recommends conditional approval of Pixuvri

TCG Lifesciences chooses preclinical development candidate

CHMP recommends approval of Byetta line extension

FDA approves first medical therapy for endogenous Cushing's syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...